High-power KTP laser prostatectomy: the new challenge to transurethral resection of the prostate.
OBJECTIVE
The quest for a successful surgical modality that can be used in the day-case setting, with minimal risk of complications and without the need for postoperative catheter drainage, may finally be fulfilled in the form of the new-generation, high-power potassium titanyl phosphate (KTP) lasers. In this review we will trace the development of KTP laser technology and its use by urologists over the years and describe why its physical properties make it so different from the lasers of the past.


RESULTS
The most high powered (80 W) incarnation has a relatively short history, particularly in terms of peer-reviewed publications. We will, however, outline the data so far and demonstrate what an exciting tool this represents for the urologist not only in terms of qualitative and quantitative improvements in lower urinary tract symptoms, but also in offering a day case, and in some instances catheterless, procedure with the prospect of a significantly lower impact on sexual function compared with standard surgical options.


CONCLUSIONS
Despite the lack of long-term data it is certainly possible that high-power KTP lasers represent a very significant challenge to the 'gold standard' status of transurethral resection of the prostate. Furthermore, the ability to use this technology to safely and effectively treat very large prostates represents an opportunity to assign the associated morbidity of the open prostatectomy to the annals of history.
Barber
Neil J
NJ
Department of Urology, King's College Hospital, London, UK.
Muir
Gordon H
GH
D000368:Aged; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004285:Dogs; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000009:adverse effects / Q000379:methods; D011468:Prostatectomy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000601:surgery*; D018570:Risk Assessment; D012720:Severity of Illness Index; D014025:Titanium / Q000494:pharmacology; D020728:Transurethral Resection of Prostate / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D014563:Urodynamics
D014025:Titanium